The FDA still could decide to approve the drug, aducanumab, making it the first new Alzheimer's treatment in decades. Several of the 11 panel members expressed resentment that the FDA's early view of aducanumab - which was made public on Wednesday - was biased toward a favorable outcome for Biogen.